Advanced visualization and artificial intelligence (AI) software developer TeraRecon has rebranded its AI offerings and adopted the Eureka AI technology brand name of its parent company, SymphonyAI.
The rebranding reflects TeraRecon's intent to leverage the Eureka brand and to develop new collaborative offerings involving, for example, unsupervised machine learning and curated patient data, according to the firm. TeraRecon was acquired by SymphonyAI, a group of business-to-business AI companies, in March.
As a result of the transition, TeraRecon's EnvoyAI and Northstar brand names will be retired in favor of the Eureka branding. However, these technologies remain as the foundation of TeraRecon's AI portfolio and are now part of a greater technology ecosystem, according to the vendor.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
